相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advances in immunotherapy for the treatment of glioblastoma
Amanda Tivnan et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
ATIM-04. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM
David Reardon et al.
NEURO-ONCOLOGY (2017)
OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143
A. Omuro et al.
NEURO-ONCOLOGY (2017)
Immune Checkpoint in Glioblastoma: Promising and Challenging
Jing Huang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers
Hans Vasen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia
K. S. Schwab et al.
CASE REPORTS IN ONCOLOGY (2016)
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
Amruth R. Palla et al.
CASE REPORTS IN ONCOLOGY (2016)
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma
Gordana Vlahovic et al.
NEURO-ONCOLOGY (2015)
Releasing the Brakes on Cancer Immunotherapy
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2015)
分享论文
